Adargiminase
Adargiminase (NEI-01) is a modified arginine-depleting enzyme and albumin binder. Adargiminase catalyzes the conversion of arginine to citrulline and ammonia, reduces plasma arginine levels to undetectable levels, and binds to serum albumin from Mus musculus (mouse), Rattus norvegicus (rat), Canis lupus familiaris (dog) and Homo sapiens (human) to extend its half-life. Adargiminase inhibits the viability of ASS1-negative pancreatic cancer cells, and reduces tumor volume and weight. Adargiminase can be used for the research of pancreatic cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Adargiminase (0.001-10 μg/mL; 72 h) potently inhibits the viability of ASS1-negative MIA PaCa-2 and PANC-1 pancreatic cancer cells, but exerts no inhibitory effect on ASS1-positive SMMC7721 hepatocellular carcinoma cells[1].
Adargiminase (0.1 μg/mL; 6-96 h) induces activation of the autophagy pathway (increased levels of LC3-II, Beclin 1, and phosphorylated AMPKα) and activation of the apoptosis pathway (decreased level of PARP-1) in MIA PaCa-2 pancreatic cancer cells[1].
Adargiminase (0.001-1 μg/mL; 72 h) has no effect on NEI-01-adapted MIA PaCa-2 pancreatic cancer cells, but resensitizes these cells after 96 h of culture in NEI-01-free medium[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human pancreatic cancer cell lines (MIA PaCa-2, PANC-1), human hepatocellular carcinoma cell line (SMMC7721)
-
Concentration:0.001-10 μg/mL
-
Incubation Time:72 h
-
Result:Inhibited viability of ASS1-negative MIA PaCa-2 cells with an IC50 of 0.086 μg/mL.
Inhibited viability of ASS1-negative PANC-1 cells with an IC50 of 0.190 μg/mL.
Showed no significant inhibition of ASS1-positive SMMC7721 cells, with an IC50 >10 μg/mL.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cell line
-
Concentration:0.1 μg/mL
-
Incubation Time:6-96 h
-
Result:Increased levels of LC3-II, Beclin 1, and phospho-AMPKα.
Decreased levels of PARP-1.
Indicated activation of both autophagic and apoptotic pathways.
-
Cell Line:NEI-01-adapted and washout MIA PaCa-2 human pancreatic cancer cell line
-
Concentration:0.001-1 μg/mL
-
Incubation Time:72 h
-
Result:Showed resistance to NEI-01 treatment in NEI-01-adapted MIA PaCa-2 cells.
Resensitized washout MIA PaCa-2 cells to NEI-01 with an IC50 of 0.012 μg/mL.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c female athymic nude mice (4-6-week-old; pancreatic cancer xenograft model)[1]
-
Dosage:2 U; 5 U
-
Administration:i.p.; twice a week
-
Result:Significantly reduced tumor volume compared to control (2 U dose).
Significantly reduced tumor volume (p < 0.01) and tumor weight (p = 0.004) compared to control (5 U dose).
Reduced plasma arginine levels over the course of the experiment.
Induced only a very slight increase in ASS1 expression in tumor tissue.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[Adargiminase]
-
Synonyms
NEI-01
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Adargiminase Related Classifications
Cat. No.: HY-P992098
Powered by Bioz
- Adargiminase
- NEI-01
- NEI01
- NEI 01
- Protein Arginine Deiminase
- human pancreatic mouse xenograft models
- dog serum albumin
- rat serum albumin
- ASS1-negative pancreatic cancer cells
- mouse serum albumin
- MIA PaCa-2 pancreatic cancer cells
- autophagic pathways
- ASS1-positive SMMC7721 hepatocellular carcinoma cells
- apoptotic pathways
- PANC-1 pancreatic cancer cells
- Inhibitor
- inhibitor
- inhibit